Marc Matrana, MD shares his perspective on an mCSPC patient case, focusing on the typical trajectory for patients with biochemical recurrence.
A 58-Year-Old Man with Biochemically Recurrent Metastatic Castration-Sensitive Prostate Cancer
A prostate cancer expert shares a brief overview of available first-line therapy options for patients with mCSPC.
Clinical insights concerning the selection of effective treatment approaches for patients with mCSPC with comments on the study design and results of the TITAN study.
Discussion centered around androgen receptor inhibition/androgen synthesis inhibition and comparison of available, approved options for each.
An experienced clinician expands on effective strategies for monitoring patients with mCSPC during and after treatment and reviews patient expectations following disease progression.
Insight on recent developments and emerging options in the mCSPC treatment landscape.
Dr. Marc Matrana closes the discussion with considerations for clinicians on treating patients with prostate cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
